Exploring the Potential Drug Target and Biomarker ELP2 (ELP2 Variant 2)

Target Name: ELP2

NCBI ID: G55250

ELP2

Exploring the Potential Drug Target and Biomarker ELP2 (ELP2 Variant 2)

Eryloidin (ELP) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. One of the variants of the ELP protein is ELP2 (ELP2 Variant 2), which has unique properties compared to the parental ELP protein. In this article, we will explore the potential drug target and biomarker properties of ELP2 and its potential in the treatment of various diseases.

Structure and Function

The ELP protein is a member of the Integrin 伪6 (IAA) family, which is involved in cell adhesion, migration, and invasion. ELP1 and ELP2 are the most well-studied members of the IAA family, and they differ in their sequence and localization. ELP1 is a 21-kDa protein that is predominantly expressed in the brain and pancreas, while ELP2 is a 19-kDa protein that is predominantly expressed in the skin, gut, and breast tissue.

ELP2 has unique properties compared to the parental ELP protein. One of the most significant differences is its altered expression level in various tissues. ELP2 is expressed in higher levels in the skin, gut, and breast tissue compared to the brain and pancreas. Additionally, ELP2 is known to have a different localization and structure compared to ELP1. ELP2 has a different C-terminus compared to ELP1, which may affect its stability and function in the body.

Drug Target Potential

The unique properties of ELP2 make it an attractive drug target. ELP2 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. Additionally, ELP2 has been linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One potential mechanism by which ELP2 may be targeted as a drug is its role in cell adhesion. ELP2 has been shown to be involved in the formation of tight junctions, which are a type of cell-cell adhesion that is critical for various physiological processes, including tissue repair and regeneration. By targeting ELP2, drugs may be able to disrupt these processes and potentially have therapeutic effects on various diseases.

Another potential mechanism by which ELP2 may be targeted as a drug is its role in cancer progression. ELP2 has been shown to be involved in various cellular processes that promote cancer cell growth and survival, including the regulation of apoptosis (programmed cell death). By targeting ELP2, drugs may be able to disrupt these processes and potentially have therapeutic effects on cancer growth and progression.

Biomarker Potential

ELP2 has also been identified as a potential biomarker for various diseases. One potential mechanism by which ELP2 may be used as a biomarker is its role in the regulation of inflammation. ELP2 has been shown to be involved in the regulation of various cellular processes that control inflammation, including the production of pro-inflammatory cytokines. By targeting ELP2, drugs may be able to disrupt these processes and potentially have therapeutic effects on various inflammatory diseases.

ELP2 has also been shown to be involved in the regulation of fibrosis, which is a process by which cells become abnormally persistent and cause various diseases, including cancer. By targeting ELP2, drugs may be able to disrupt these processes and potentially have therapeutic effects on various fibrotic diseases.

Conclusion

In conclusion, ELP2 is a protein that has unique properties compared to the parental ELP protein. ELP2 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion, and has been linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, ELP2 has

Protein Name: Elongator Acetyltransferase Complex Subunit 2

Functions: Component of the elongator complex which is required for multiple tRNA modifications, including mcm5U (5-methoxycarbonylmethyl uridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), and ncm5U (5-carbamoylmethyl uridine) (PubMed:29332244). The elongator complex catalyzes the formation of carboxymethyluridine in the wobble base at position 34 in tRNAs (PubMed:29332244)

The "ELP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets